OR WAIT null SECS
OARSI 2019: Phase IIIb clinical trial for the extended release injectable triamcinolone acetonide (Zilretta, Flexion) shows improvement in pain, stiffness and function.
Flexion Therapeutics, Inc., presented the results of a phase IIIb trial for the extended release injectable triamcinolone acetonide (Zilretta, Flexion) this weekend in Toronto at the Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis.
The study found that 60 percent of osteoarthritis patients demonstrated an analgesic response after two injections with a more than 50 percent improvement in pain, stiffness and function. In a safety study of triamcinolone acetonide for hip osteoarthritis, no new safety concerns were found.
The treatment “resulted in lower peak plasma levels and reduced systemic exposure relative to triamcinolone acetonide crystalline suspension, a pattern similarly observed in knee OA.” (©Kikkerdirk, AdobeStock)